Literature DB >> 1568817

Morphea with high titer of fibronectin antibodies.

C M Stefanato1, A Gorkiewicz-Petkow, M Jarzabek-Chorzelska, S Jablonska, T Chorzelski.   

Abstract

A 20-year-old man with a 9-year history of unusual subcutaneous morphea with nodular lesions in a circular arrangement and wooden-hard symmetrical induration of the arms, had high titers of fibronectin antibodies. A possible role of fibronectin and antifibronectin antibodies in the pathogenesis of scleroderma is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568817     DOI: 10.1111/j.1365-4362.1992.tb03933.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.

Authors:  M S Atta; K L Lim; D A Ala'deen; R J Powell; I Todd
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

2.  The influence of anti-fibronectin antibodies on interactions involving extracellular matrix components and cells: a possible pathogenic mechanism.

Authors:  M S Atta; R J Powell; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

3.  Human anti-fibronectin antibodies in systemic lupus erythematosus: occurrence and antigenic specificity.

Authors:  M S Atta; R J Powell; N D Hopkinson; I Todd
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

4.  Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma.

Authors:  B Eckes; C Mauch; G Hüppe; T Krieg
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

5.  Development of keloidal morphea after treatment with cyclosporine in a case of recalcitrant generalized morphea.

Authors:  Sahar Dadkhahfar; Zahra Asadi Kani; Farnaz Araghi; Hamideh Moravvej
Journal:  Clin Case Rep       Date:  2020-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.